SUGAR LAND, Texas, Oct. 02, 2018 /PRNewswire-PRWeb/ -- In a recently published randomized controlled study, TransLite's
The clinical study was completed by Merve Gümü?, RN, MSc and Zümrüt Ba?bakkal, PhD, on a sample of 110 pediatric patients (58 boys and 52 girls), between the ages of 1 and 10. PIC intervention is widely regarded to be a challenging task, especially among children, who have smaller blood vessels, more adipose tissue, and are more difficult to communicate with.
The conclusion states, "The use of new technology in the Veinlite PEDI to assist with peripheral IV access in children improves the first time success rate for IV access. These results suggest that the new technology of the Veinlite results in better PIC access."
These results demonstrate the efficacy of Veinlite PEDI® in improving patient satisfaction and enabling medical professionals to be more effective in the process.
Veinlite PEDI is a compact, portable vein access device featuring red and orange lights that can be used in side-transillumination or through-the-body visualization. It can be used anywhere on the body, including the scalp.
Veinlite PEDI also meets INS Guidelines for infection control, a critical consideration when providing healthcare treatment to any patient. Veinlite PEDI is available immediately. US customers can purchase direct from the company's website, veinlite.com (includes an exclusive five-year extended warranty). For customers in other countries and territories, please see Veinlite's Authorized International Distributors.
To learn more about Veinlite PEDI® or TransLite's complete line of IV access and Sclerotherapy vein finders visit https://www.veinlite.com. For more information or to schedule an interview, contact Kristin Mullani at (281) 240-3111 or info(at)veinlite(dot)com
SOURCE TransLite LLC
Subscribe to our Free Newsletters!